PubMed:23984894 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue
SS1_23984894_1_0	77-117	expanded	denotes	Chemotherapy-induced nausea and vomiting
SS2_23984894_1_0	119-123	abbr	denotes	CINV
AE1_23984894_1_0	SS1_23984894_1_0	SS2_23984894_1_0	abbreviatedTo	Chemotherapy-induced nausea and vomiting,CINV

Id	Subject	Object	Predicate	Lexical cue
T1	77-238	DRI_Background	denotes	Chemotherapy-induced nausea and vomiting (CINV) remains both a feared side effect of cancer treatment and a focus of many supportive care initiatives/guidelines.
T2	239-410	DRI_Background	denotes	The class of medications known as serotonin receptor antagonists (5-HT3RAs) are integral in the prevention of CINV from both moderately and highly emetogenic chemotherapy.
T3	411-698	DRI_Background	denotes	Palonosetron (ALOXI(®)), a second-generation 5-HT3RA, has a higher affinity for the 5-HT3 receptor, has a longer half-life and has unique interactions with the 5-HT3 receptor compared with the current first-generation 5-HT3RA such as ondansetron, granisetron, dolasetron and tropisetron.
T4	699-759	DRI_Approach	denotes	This may allow palonosetron an advantage in control of CINV.
T5	760-908	DRI_Outcome	denotes	This review article examines the available evidence, the pharmacokinetics and the safety and tolerability of palonosetron in the prevention of CINV.

Id	Subject	Object	Predicate	Lexical cue
T1	98-104	HP_0002018	denotes	nausea
T2	109-117	HP_0002013	denotes	vomiting
T3	162-168	HP_0002664	denotes	cancer